We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+2.85%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$14.8B
AUM Growth
+$2.92B
(+25%)
Cap. Flow
+$3.28B
Cap. Flow
% of AUM
22.14%
Top 10 Holdings %
Top 10 Hldgs %
12.56%
Holding
1,029
New
443
Increased
269
Reduced
185
Closed
112
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$217M |
| 2 |
Apple
AAPL
|
+$208M |
| 3 |
Microsoft
MSFT
|
+$199M |
| 4 |
Amazon
AMZN
|
+$136M |
| 5 |
Arthur J. Gallagher & Co
AJG
|
+$133M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$125M |
| 2 |
Gilead Sciences
GILD
|
+$107M |
| 3 |
PR
Permian Resources
PR
|
+$85.4M |
| 4 |
Reddit
RDDT
|
+$84.1M |
| 5 |
Keysight
KEYS
|
+$79M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.96% |
| 2 | Technology | 25.64% |
| 3 | Financials | 7.58% |
| 4 | Industrials | 6.88% |
| 5 | Communication Services | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CPRX
476
DELISTED
Catalyst Pharmaceutical
CPRX
| $5.28M | 0.04% |
252,969
-53,489
| -17% | -$1.15M |
|
|
AVDL
477
DELISTED
Avadel Pharmaceuticals
AVDL
| $5.27M | 0.04% |
501,821
-1,185,492
| -70% | -$14.4M |
|
478
Jasper Therapeutics
JSPR
$23.6M
| $5.25M | 0.04% |
245,676
-249,428
| -50% | -$5.19M |
|
479
Eaton
ETN
$174B
| $5.22M | 0.04% |
15,744
-188,330
| -92% | -$66.1M |
|
480
American Tower
AMT
$80.4B
| $5.22M | 0.04% |
+28,456
| New | +$5.9M |
|
481
PayPal
PYPL
$50.5B
| $5.16M | 0.03% |
+60,403
| New | +$5.08M |
|
482
Intercontinental Exchange
ICE
$84.4B
| $5.14M | 0.03% |
+34,482
| New | +$5.46M |
|
|
WCC
483
WESCO International
WCC
$17.7B
| $5.14M | 0.03% |
+28,381
| New | +$5.37M |
|
484
Brinker International
EAT
$9.66B
| $5.12M | 0.03% |
38,737
+20,302
| +110% | +$2.28M |
|
485
Nike
NKE
$61.9B
| $5.09M | 0.03% |
67,308
-376,723
| -85% | -$29.6M |
|
486
CME Group
CME
$94.8B
| $5.03M | 0.03% |
+21,641
| New | +$4.98M |
|
487
Duke Energy
DUK
$97.3B
| $5M | 0.03% |
+46,391
| New | +$5.26M |
|
488
Cirrus Logic
CRUS
$6.26B
| $5M | 0.03% |
+50,189
| New | +$5.51M |
|
489
Liquidia Corp
LQDA
$8.02B
| $4.96M | 0.03% |
421,683
+6,791
| +2% | +$74.2K |
|
490
GDS Holdings
GDS
$6.41B
| $4.88M | 0.03% |
+205,277
| New | +$4.33M |
|
491
RingCentral
RNG
$5.28B
| $4.86M | 0.03% |
138,956
+20,799
| +18% | +$747K |
|
|
BCAX
492
Bicara Therapeutics
BCAX
$1.84B
| $4.8M | 0.03% |
275,692
-2,277
| -0.8% | -$47.4K |
|
493
Mondelez International
MDLZ
$79.9B
| $4.8M | 0.03% |
+80,304
| New | +$5.31M |
|
494
Cogent Biosciences
COGT
$7.24B
| $4.78M | 0.03% |
613,165
+12,589
| +2% | +$125K |
|
495
Sherwin-Williams
SHW
$89.8B
| $4.73M | 0.03% |
+13,915
| New | +$5.19M |
|
496
Coty
COTY
$2.48B
| $4.72M | 0.03% |
+678,663
| New | +$5.22M |
|
497
Lifestance Health
LFST
$4.14B
| $4.66M | 0.03% |
632,301
-691,089
| -52% | -$4.96M |
|
498
Forte Biosciences
FBRX
$1.57B
| $4.64M | 0.03% |
+204,275
| New | +$2.43M |
|
499
Motorola Solutions
MSI
$77.4B
| $4.64M | 0.03% |
+10,036
| New | +$4.76M |
|
500
Lockheed Martin
LMT
$136B
| $4.63M | 0.03% |
+9,533
| New | +$5.2M |
|
Similar funds
TCIIS
UIM
VAI
KK
Woodline Partners's Q4 2024 Portfolio in Review
As of Q4 2024, Woodline Partners held 1,029 positions worth $14.8B, up 25% from $11.9B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Woodline Partners deployed $3.28B of net new capital in Q4 2024, opening 443 new positions and adding to 269 existing holdings. Its largest new stake was TE Connectivity: 890,754 shares worth $127M.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 43% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Gilead Sciences, an estimated $107M trimmed.
- Woodline Partners's largest Q4 2024 buy was TE Connectivity: 890,754 shares worth $127M.
- Woodline Partners added most to NVIDIA in Q4 2024, an estimated $217M increase.
- Woodline Partners's biggest Q4 2024 reduction was Gilead Sciences, cutting an estimated $107M.
- Woodline Partners fully exited ASML in Q4 2024, selling an estimated $125M.
- Woodline Partners's ten largest holdings make up 13% of its $14.8B portfolio in Q4 2024.
- Woodline Partners opened 443 new positions and closed 112 in Q4 2024.
- Woodline Partners's portfolio value rose 25% quarter-over-quarter to $14.8B.
Based on Woodline Partners's 13F filing for Q4 2024, filed 14 Feb 2025.